Clinical Trial

Deucravacitinib in the Treatment of Cicatricial Alopecias

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label clinical trial, in which all participants will be treated with deucravacitinib for 48 weeks. Approximately 20 participants will be enrolled: 10 Central Centrifugal Cicatricial Alopecia (CCCA) and 10 Frontal Fibrosing Alopecia (FFA). The study will take place at the Icahn School of Medicine at Mount Sinai (ISMMS). At the Baseline/Day 0 visit, participants will initiate treatment with deucravacitinib. All participants will receive deucravacitinib 12mg once-daily for 48 weeks. The treatment period will conclude at week 48.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-12
notable Primary completion pushed: 2026-09-30 -> 2028-06-30 2026-05-12
minor Completion pushed: 2027-01-21 -> 2028-09-30 2026-05-12
Trial Details
NCT Number NCT07508488
Lead Sponsor Icahn School of Medicine at Mount Sinai
Collaborators: Bristol-Myers Squibb
Conditions Central Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia
Enrollment 20 participants
Start Date 2026-05-28
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-10